Home › Research › Biomarkers
Performance of blood biomarkers in internal jugular vein for Alzheimer's disease pathologies: the Delta Method study
Jun Wang, Dong-Yu Fan, Shan Huang, Chang Liu, Pei-Wen Zhao, Nan Wu, Xiao-Lin Gao, Qing-Zhi Wang et al.. Science bulletin, 2025-10-30
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
Systemic factors confound blood tests for the diagnosis of Alzheimer's disease (AD). The Delta Method study explored whether blood biomarkers from the vein proximal to the brain perform better in detecting cerebral Alzheimer's pathologies using PET or cerebrospinal fluid (CSF) biomarkers as reference standards in two independent cohorts (n = 463). Blood was collected from the internal jugular vein (IJV) and median cubital vein (MCV), and AD biomarkers were measured with Lumipulse G and Simoa methods. The results showed that the levels of Aβ42, Aβ40, p-tau217, p-tau181, GFAP, and NfL were higher in the IJV than in MCV and were highly correlated between the two sites. IJV-Aβ42/40 had stronger correlations with Aβ PET Centiloids and tau PET meta-temporal SUVR than MCV-Aβ42/40. In detecting cerebral Aβ positivity, IJV-Aβ42/40 demonstrated a significantly higher accuracy (79.9%-92.9% vs. 72.4%-88.8%) and a lower percentage of uncertain individuals (17.8%-54.5% vs. 31.3%-70.1%) than MCV-Aβ42/40. Moreover, the diagnostic accuracy of Lumipulse G IJV-Aβ42/40 (88.2%-92.9%) was statistically equivalent to that of MCV-p-tau217 (90.2%-94.3%), although the intermediate percentage of IJV-Aβ42/40 was higher (17.8%-34.0% vs. 0.7%-17.5%). These findings were verified in the validation cohort. This study demonstrated the superior performance of IJV-Aβ42/40 to MCV-Aβ42/40 in detecting cerebral Alzheimer's pathologies, offering a novel perspective to reduce the impacts of systemic factors and comorbidities on blood tests.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Wang, J., Fan, D.-Y., Huang, S., Liu, C., Zhao, P.-W., Wu, N., et al. (2025). Performance of blood biomarkers in internal jugular vein for Alzheimer's disease pathologies: the Delta Method study. Science bulletin. https://doi.org/10.1016/j.scib.2025.10.044
Vancouver
Wang J, Fan D.-Y, Huang S, Liu C, Zhao P.-W, Wu N, et al. Performance of blood biomarkers in internal jugular vein for Alzheimer's disease pathologies: the Delta Method study. Science bulletin. 2025. doi:10.1016/j.scib.2025.10.044. PMID: 41207832.
BibTeX
@article{wang2025-41207832,
author = {Wang, Jun and Fan, Dong-Yu and Huang, Shan and Liu, Chang and Zhao, Pei-Wen and Wu, Nan and Gao, Xiao-Lin and Wang, Qing-Zhi and others},
title = {{Performance of blood biomarkers in internal jugular vein for Alzheimer's disease pathologies: the Delta Method study}},
journal = {Science bulletin},
year = {2025},
doi = {10.1016/j.scib.2025.10.044},
pmid = {41207832},
url = {https://doi.org/10.1016/j.scib.2025.10.044}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The results showed that the levels of Aβ42, Aβ40, p-tau217, p-tau181, GFAP, and NfL were higher in the IJV than in MCV and were highly correlated between the two sites.
- In detecting cerebral Aβ positivity, IJV-Aβ42/40 demonstrated a significantly higher accuracy (79.9%-92.9% vs. 72.4%-88.8%) and a lower percentage of uncertain individuals (17.8%-54.5% vs. 31.3%-70.1%) than MCV-Aβ42/40.
- These findings were verified in the validation cohort.
- This study demonstrated the superior performance of IJV-Aβ42/40 to MCV-Aβ42/40 in detecting cerebral Alzheimer's pathologies, offering a novel perspective to reduce the impacts of systemic factors and comorbidities on blood tests.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants463
- Effect size79.9%; 92.9%; 72.4%
- Evidence strengthModerate
How this study scored 59/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 33 of the 56 points we could judge it on, which is 59 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Science bulletin) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 463 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41207832) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 33 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 33 of the 56 points we could judge it on is 59 out of 100. |
| Total | 59 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “p-tau217”
692 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 692 tagged studies.